Supernus Pharmaceuticals (SUPN) Change in Receivables (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Change in Receivables data on file, last reported at -$5.6 million in Q1 2026.

• On a quarterly basis, Change in Receivables fell 257.7% year-over-year to -$5.6 million in Q1 2026; TTM through Mar 2026 was $13.1 million, a 726.65% increase from a year earlier, with the FY2025 full-year figure at $22.3 million, up 1173.34% from the prior year.
• Change in Receivables for Q1 2026 stood at -$5.6 million, down from $16.4 million in the prior quarter.
• Over the last five years, Change in Receivables for SUPN reached as high as $16.4 million in Q4 2025 and fell as low as -$22.0 million in Q1 2023.
• Historically, Change in Receivables has averaged $718117.6 across 5 years, with a median of $2.4 million in 2023.
• Across the five-year window, Change in Receivables slumped 476.36% in 2023 and surged 592.92% in 2025, its largest moves.
• Year by year, Change in Receivables stood at $1.4 million in 2022, then soared by 69.74% to $2.4 million in 2023, then tumbled by 239.37% to -$3.3 million in 2024, then jumped by 592.92% to $16.4 million in 2025, then plunged by 134.22% to -$5.6 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were -$5.6 million in Q1 2026, $16.4 million in Q4 2025, and $7.1 million in Q3 2025.